73 related articles for article (PubMed ID: 19457660)
1. Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
Burns DM; Li YL; Shi E; He C; Xu M; Zhuo J; Zhang C; Qian DQ; Li Y; Wynn R; Covington MB; Katiyar K; Marando CA; Fridman JS; Scherle P; Friedman S; Metcalf B; Yao W
Bioorg Med Chem Lett; 2009 Jul; 19(13):3525-30. PubMed ID: 19457660
[TBL] [Abstract][Full Text] [Related]
2. Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.
Yao W; Zhuo J; Burns DM; Li YL; Qian DQ; Zhang C; He C; Xu M; Shi E; Li Y; Marando CA; Covington MB; Yang G; Liu X; Pan M; Fridman JS; Scherle P; Wasserman ZR; Hollis G; Vaddi K; Yeleswaram S; Newton R; Friedman S; Metcalf B
Bioorg Med Chem Lett; 2008 Jan; 18(1):159-63. PubMed ID: 18036818
[TBL] [Abstract][Full Text] [Related]
3. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
4. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
[TBL] [Abstract][Full Text] [Related]
5. ADAM10 and ADAM17: New players in trastuzumab tesistance.
Duffy MJ; Crown J; Mullooly M
Oncotarget; 2014 Nov; 5(22):10963-4. PubMed ID: 25460503
[No Abstract] [Full Text] [Related]
6. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
Yao W; Zhuo J; Burns DM; Xu M; Zhang C; Li YL; Qian DQ; He C; Weng L; Shi E; Lin Q; Agrios C; Burn TC; Caulder E; Covington MB; Fridman JS; Friedman S; Katiyar K; Hollis G; Li Y; Liu C; Liu X; Marando CA; Newton R; Pan M; Scherle P; Taylor N; Vaddi K; Wasserman ZR; Wynn R; Yeleswaram S; Jalluri R; Bower M; Zhou BB; Metcalf B
J Med Chem; 2007 Feb; 50(4):603-6. PubMed ID: 17256836
[TBL] [Abstract][Full Text] [Related]
7. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
8. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.
Moss ML; Rasmussen FH
Anal Biochem; 2007 Jul; 366(2):144-8. PubMed ID: 17548045
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
12. MMP-2 selectivity in hydroxamate-type inhibitors.
Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
[TBL] [Abstract][Full Text] [Related]
14. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
[TBL] [Abstract][Full Text] [Related]
16. Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.
Burns DM; He C; Li Y; Scherle P; Liu X; Marando CA; Covington MB; Yang G; Pan M; Turner S; Fridman JS; Hollis G; Vaddi K; Yeleswaram S; Newton R; Friedman S; Metcalf B; Yao W
Bioorg Med Chem Lett; 2008 Jan; 18(2):560-4. PubMed ID: 18068976
[TBL] [Abstract][Full Text] [Related]
17. The metalloproteinase-disintegrin ADAM10 is exclusively expressed by type I muscle fibers.
Dehmel T; Goebel HH; Hartung HP; Lehmann H; Wiendl H; Kieseier BC
Muscle Nerve; 2008 Aug; 38(2):1049-51. PubMed ID: 18642355
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of ADAM 10 and ADAM 12 in lesional psoriatic skin.
Oh ST; Schramme A; Stark A; Tilgen W; Gutwein P; Reichrath J
Br J Dermatol; 2008 Jun; 158(6):1371-3. PubMed ID: 18363768
[No Abstract] [Full Text] [Related]
19. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
